UroGen Pharma-Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates

Urogen Pharma (URGN) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of$ 0.82. This compares to loss of $1.03 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -10.98%. A quarter ago, it was expected that this company would post a loss of$ 0.93 per share when it actually produced a loss of $0.97, delivering a surprise of -4.30%. Over the last four quarters, the company has surpasse ...